Research To Practice | Oncology Videos

View Top 200 Chart

Back to Rankings Page

Science
**Research To Practice | Oncology Videos**

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Latest Episodes:

Hepatocellular Carcinoma — Fourth Annual National General Medical Oncology Summit Jun 01, 2025

Show notes

Featuring perspectives from Dr Thomas A Abrams and Dr Ahmed Omar Kaseb, including the following topics:

Current Treatment for Advanced Hepatocellular Carcinoma (HCC) — Dr Abrams (0:00)
Promising Novel Approaches to HCC Management — Dr Kaseb (33:46)

CME information and select publications

Multiple Myeloma — Fourth Annual National General Medical Oncology Summit May 31, 2025

Show notes

Featuring perspectives from Dr Natalie S Callander and Dr Thomas Martin, including the following topics:

Introduction (0:00)
Current and Emerging Therapeutic Approaches for Multiple Myeloma — Dr Callander (4:42)
CAR T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Martin (31:16)

CME information and select publications

For Oncology Nurses: Pancreatic Cancer — Proceedings from the 2025 Annual ONS Congress May 30, 2025

Show notes

Featuring perspectives from Dr Farshid Dayyani, Ms Caroline Kuhlman, Dr Philip A Philip and Ms Amanda K Wagner, including the following topics:

Introduction: Initial Management of Pancreatic Adenocarcinoma (PAD) (0:00)
Clinical Presentation and Prognosis of PAD; Recent Advances in Up-Front Treatment for Metastatic PAD (19:01)
Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD (54:38)
Importance of Palliative Care for Advanced PAD (1:06:09)
Role of PARP Inhibitor Maintenance Therapy for Newly Diagnosed Metastatic PAD (1:14:59)
Promising Investigational Strategies for PAD (1:26:56)

NCPD information and select publications

Multiple Myeloma — An Interview with Dr Rafael Fonseca on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting May 29, 2025

Show notes

Featuring an interview with Dr Rafael Fonseca, including the following topics:

Safe management of bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma (MM) (0:00)
Sequencing bispecific antibodies and CAR T-cell therapy (10:40)
Available data with and potential future clinical integration of belantamab mafodotin in the management of MM (16:03)
Optimizing maintenance therapy for patients with MM (31:11)
Novel management strategies for smoldering myeloma (36:29)
Role of anti-CD38 antibodies in the up-front management of MM (41:41)
Available data with cereblon E3 ligase modulatory drugs for MM (47:45)

CME information and select publications

Multiple Myeloma — An Interview with Dr Rafael Fonseca on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting (Companion Faculty Lecture) May 29, 2025

Show notes

Featuring a slide presentation and related discussion from Dr Rafael Fonseca, including the following topics:

Recent updates from ASH 2024 on the up-front use of anti-CD38 monoclonal antibodies for multiple myeloma (MM) (0:00)
Updated data with belantamab mafodotin for the management of MM (12:39)
Updated findings with chimeric antigen receptor T cell therapy for the management of MM (17:52)
ASH 2024 updates with other novel agents and strategies for the management of MM (21:32)

CME information and select publications

5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer May 27, 2025

Show notes

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics:

Evaluating first-line treatment of metastatic ER-positive, HER2-positive breast cancer: heredERA Breast Cancer study (0:00)
- Kuemmel S et al. heredERA Breast Cancer: A phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer 2024;24(1):641. Abstract
Treatment outcomes with CDK4/6 inhibitors and with elacestrant in real-world studies (4:13)
- Lloyd MR et al. CDK4/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid 2024;3(5). Abstract
- Lloyd M et al. Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC). San Antonio Breast Cancer Symposium 2024;Abstract PS7-05.
Evaluating the CNS activity of imlunestrant, an oral selective estrogen receptor degrader (SERD) (8:06)
- VandeKopple M et al. Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model. ESMO Breast 2023;Abstract 41P.
Selective review of trials of oral SERDs in the adjuvant setting (11:27)
- A study of imlunestrant versus standard endocrine therapy in participants with early breast cancer (EMBER-4). NCT05514054

CME information and select publications

Gastroesophageal Cancer — Fourth Annual National General Medical Oncology Summit May 26, 2025

Show notes

Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, MD, including the following topics:

Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers — Dr Janjigian (0:00)
Available and Emerging Targeted Therapeutic Approaches for Gastroesophageal Cancers — Dr Klempner(28:38)

CME information and select publications

Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting May 25, 2025

Show notes

Featuring an interview with Dr Lindsey Roeker, including the following topics:

Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00)
Safety of BTK inhibitors in older and frail patients with CLL (3:41)
Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20)
Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32)
Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31)
Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16)
Sequencing, tolerability and future development involving pirtobrutinib (25:57)
Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28)
Clinical considerations in the management of Richter's transformation (38:14)
Survival outcomes and quality of life for patients with CLL (41:02)
Ongoing and future efforts to improve CLL treatment outcomes (45:01)

CME information and select publications

Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting (Companion Faculty Lecture) May 24, 2025

Show notes

Featuring a slide presentation and related discussion from Dr Lindsey Roeker, including the following topics:

Recent clinical updates with standard regimens for chronic lymphocytic leukemia (CLL) (0:00)
Utility of minimal residual disease-guided treatment intensification after ibrutinib with venetoclax (7:03)
Major long-term findings from the GLOW study of ibrutinib with venetoclax (10:35)
Principal findings from the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab (12:28)
Findings with combined acalabrutinib, venetoclax and obinutuzumab for patients with previously untreated high-risk disease (15:52)
Early clinical findings with sonrotoclax and zanubrutinib as front-line treatment for CLL (18:12)
Principal findings from the BRUIN CLL-321 trial of pirtobrutinib for patients who previously received a covalent Bruton tyrosine kinase (BTK) inhibitor (19:38)
Emerging evidence with pirtobrutinib, venetoclax and obinutuzumab as front-line treatment (22:15)
Novel strategy combining lisocabtagene maraleucel with ibrutinib for relapsed/refractory (R/R) CLL (24:13)
Available data with epcoritamab monotherapy for R/R CLL (26:58)
The emerging pharmacologic class of BTK degraders (29:04)

CME information and select publications

Relapsed/Refractory Follicular Lymphoma Part 3 — A Roundtable Discussion on the Selection and Sequencing of Other Novel Therapies May 23, 2025

Show notes

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics:

EZH2 Inhibitors for Follicular Lymphoma (FL) (0:00)
Bruton Tyrosine Kinase Inhibitors for FL (5:43)
Anti-CD19 Antibodies for FL (9:40)
Other Novel Agents Under Clinical Development for FL (18:50)
Case: A woman in her early 80s with multiple comorbidities and relapsed FL (23:06)
Case: A man in his early 40s with high-risk progressive FL that did not achieve deep remission with prior therapy (27:07)
Case: A woman in her early 70s with rheumatoid arthritis and relapsed FL (33:46)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected